StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $39.50 | $39.25 | -0.63% | 7.5M |
| 05-12 | $39.28 | $38.55 | -1.86% | 7.7M |
| 05-13 | $38.43 | $38.71 | +0.73% | 7.7M |
| 05-14 | $38.80 | $38.90 | +0.26% | 4.4M |
| 05-15 | $38.95 | $36.19 | -7.09% | 7.4M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Each factor shows MDLN's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q1 2026 2026-03-28 | Annual 2025 2025-12-31 | Q1 2025 2025-03-29 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $7.35B | $28.43B | $6.64B | $25.51B |
Operating Income | $422.00M | $2.21B | $571.00M | $2.15B |
Net Income | $239.00M | $1.16B | $319.00M | $1.16B |
EPS (Diluted) | $0.16 | $-0.01 | Not available | Not available |
Total Assets | $39.01B | $38.48B | Not available | $35.98B |
Total Liabilities | $19.66B | $19.20B | Not available | $19.45B |
Cash & Equivalents | $2.24B | $1.94B | $840.00M | $199.00M |
Free Cash Flow OCF − CapEx | $316.00M | $1.30B | $584.00M | $1.42B |
Shares Outstanding | 824.84M | 810.00M | Not available | Not available |
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
MDLN is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.